Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin + Tislelizumab + Chemotherapy in ESCC
NCT07531979Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of becotatug vedotin in Esophageal Squamous Cell Carcinoma (ESCC) (2 cohorts), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate up to 24 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07531979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531979.